SUPN Q2 2017 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SUPNSupernus Pharmaceuticals, Inc.

$3B

Q2 2017 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$76M+50.4% YoY

Gross Profit

$72M94.9% margin

Operating Income

$26M34.4% margin

Net Income

$17M22.9% margin

EPS (Diluted)

$0.32

QoQ Revenue Growth

+31.7%

Cash Flow

Operating Cash Flow

$26M

Free Cash Flow

$25M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$346M

Total Liabilities

$117M

Stockholders' Equity

$229M

Cash & Equivalents

$93M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$76M	$50M	+50.4%
Gross Profit	$72M	$48M	+51.0%
Operating Income	$26M	$10M	+149.7%
Net Income	$17M	$10M	+69.4%